I appreciate your being with us again today.

We have not yet reached full agreement on the discussion draft in time for today's hearing.

I am optimistic that we can strengthen it further.

I just would like to make a unanimous consent request that the statement of Congresswoman Anna Eshoo as well as some questions that she is promulgating to Dr. Janet Woodcock be entered into the record.

I don't plan to use the entire time, but I come to the floor this evening basically to talk about the Affordable Care Act. Some call it the health care reform. This Friday will be the second anniversary of the President's signing of the…

I thank the gentleman from California. I have a great deal of respect for my former chairman and colleague from Texas, but as I listen to him, the problem is that it's always the same: It's my way or the highway. And it's just very…

Thank you, Mr. Chairman. I want to ask Dr. Winston, you described how the majority of research is focused on traumatic brain injury in adults and that the scientific foundation for pediatric brain injury is limited.

I look forward to the testimony, and I appreciate the fact that you held this hearing today.

Today this committee will have the opportunity to hear from some of the leading experts in the traumatic brain injury community about an update on the current landscape of traumatic brain injury prevention, research, and treatment.

It is my understanding that the treatment of traumatic brain injury is very complex and, unlike other diseases, the treatment of course has to be tailored for each individual and the outcomes can be variable as well.

Today we are holding another hearing to examine important FDA-related issues that could be considered as a part of the user fee agreements, or the UFA legislation.

I understand these provisions are intended to create Federal uniform for the regulation of these parties and could help prevent bad actors from engaging in the drug supply chain.